DNA sequencing

Precision Cancer Consortium Teams Up with Massive Bio to Utilize AI Analytics and Enhance Clinical Trial Matching for Cancer Patients Worldwide

Retrieved on: 
Friday, June 2, 2023
Oncology, Health, Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, GSK, Partnership, NGS, Roche, DNA sequencing, Clinical trial, Cancer, Multimedia, Genomics, AstraZeneca, PCC, Eli Lilly and Company, Novartis, Patient, Collection, Machine learning, Algorithm, Deep learning, Artificial intelligence, AI, Pharmaceutical industry, Medical imaging, Bayer

Massive Bio , a leading artificial intelligence (AI) analytics company specializing in precision oncology, has been selected by the Precision Cancer Consortium (PCC) , a collaboration of several global biopharmaceutical companies, to optimize clinical trial matching through their innovative AI analytics tools.

Key Points: 
  • Massive Bio , a leading artificial intelligence (AI) analytics company specializing in precision oncology, has been selected by the Precision Cancer Consortium (PCC) , a collaboration of several global biopharmaceutical companies, to optimize clinical trial matching through their innovative AI analytics tools.
  • The partnership will incorporate PCC member clinical trial protocols and patient inclusion and exclusion criteria into existing machine learning matching algorithms in SYNERGY-AI leveraged within Massive Bio’s Deep Learning Clinical Trial Matching System (DLCTMS).
  • View the full release here: https://www.businesswire.com/news/home/20230602005015/en/
    Precision Cancer Consortium Teams Up with Massive Bio to Utilize AI Analytics and Enhance Clinical Trial Matching for Cancer Patients Worldwide (Graphic: Business Wire)
    Selin Kurnaz PhD , Founder and CEO of Massive Bio, commented, "We are thrilled to be working with the Precision Cancer Consortium to advance precision oncology through our innovative AI analytics tools.
  • With this partnership, we can streamline the process of clinical trial matching and reduce the burden on patients and healthcare systems."

CENTOGENE Reports Full Year 2022 Financial Results

Retrieved on: 
Tuesday, May 16, 2023
TWIST, Galloway Mowat syndrome, IVDR, Spinal muscular atrophy, Denali, Syndrome, Audit committee, Data analysis, Patient, Fabry disease, Muscular dystrophy, Sequence, Disease, Genetics, Mass meeting, Research, Alport syndrome, Whole genome sequencing, Dysautonomia, Growth, Diagnosis, Total, Safety, DSM-IV codes, Gaucher's disease, Observational study, LRRK2, COVID-19, DNA sequencing, Supervisory board, Frontotemporal dementia, Therapy, Cancer, Epilepsy, TRE, CE, Software as a service, Hypotonia, Bank statement, Mox, Hypoventilation, Intellectual disability, Twist Bioscience, EBITDA, Physician, CNTG, Biogen, Fine chemical, Cryptocurrency, Pharmaceutical industry, Medical device, Pharma

and ROSTOCK, Germany and BERLIN, May 16, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022, and provided a business update.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, May 16, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022, and provided a business update.
  • “2022 reaffirms CENTOGENE’s focus and dedication to becoming the essential data-driven partner in rare and neurodegenerative diseases.
  • By strategically managing our expenses, we seek to enhance the stability of our balance sheet and foster sustainable financial performance,” added Miguel Coego, Chief Financial Officer at CENTOGENE.
  • These customizable partnering solutions include Insight Reports, which are tailored data analysis reports that seamlessly enable partners to answer ad hoc research questions via real-world data.

Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device

Retrieved on: 
Monday, May 1, 2023
Oncology, Health, FDA, Genetics, General Health, Pharmaceutical, Biotechnology, DNA, Microsatellite instability, NGS, DNA sequencing, Clinical trial, Cancer, Intelligence, Indel, PMA, XT, Patient, Collection, Physician, Colorectal cancer, MSI, Medicine, CDX, SNV calling from NGS data, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gene, Food, Medical device, Vaccine, Tempus

Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its companion diagnostic test, xT CDx .

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its companion diagnostic test, xT CDx .
  • xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients.
  • xT CDx is just one of the many solutions Tempus is applying to advance precision oncology.
  • For the complete xT CDx label, including companion diagnostic indications and important risk information, please visit https://www.tempus.com/resources/document-library/tempus-xt-cdx_technica... .

OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND

Retrieved on: 
Wednesday, April 26, 2023
Partnership, DNA sequencing, Infection, Research, Temperature, LMIC, Hospital, Medicine, R, Nadine Opgen-Rhein, Medical device, Curetis, Developing country

Following the delivery of a comprehensive milestone report at the end of first quarter of 2023, FIND confirmed that all requirements have been met successfully.

Key Points: 
  • Following the delivery of a comprehensive milestone report at the end of first quarter of 2023, FIND confirmed that all requirements have been met successfully.
  • Under the recently announced expansion of the collaboration, the originally planned Next Generation Sequencing (“NGS”) strain analysis will be complemented with isolates from other sub-Saharan African countries.
  • Multiple Unyvero A30 instrument adaptations were made to optimize for use in the challenging environments of low- and middle- income countries (LMICs).
  • Instrument prototypes have been designed, built and tested for operation in high-dust, extended temperature range and power-out scenarios.

CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline

Retrieved on: 
Wednesday, April 26, 2023
Software as a service, IVDR, European Parliament, European, NGS, DNA sequencing, Software, Research, Data analysis, Patient, American College of Medical Genetics and Genomics, Laboratory, Data, Physician, Medicine, Diagnosis, American College, Medical genetics, ACMG, Medical device, Pharmaceutical industry, Nursing, Genomics, Service

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 26, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of FilterTool, an advanced web-based application for genetic data interpretation.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, April 26, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of FilterTool, an advanced web-based application for genetic data interpretation.
  • The new FilterTool application seamlessly integrates with CENTOGENE’s CE-marked Software as a Service (SaaS) bioinformatics pipeline, CentoCloud®, as an accessory and enables laboratories, medical experts, and bioinformaticians to efficiently display, filter, select, and classify relevant genetic variants identified by Next Generation Sequencing (NGS) data analysis.
  • This will allow CentoCloud® users to visualize key genetic variants of concern for any given patient.
  • “The new FilterTool application is an innovation that was designed by physicians, for physicians, and when combined with CentoCloud®, significantly accelerates genetic variant interpretation.

DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023

Retrieved on: 
Sunday, April 16, 2023
KRAS, Sanger, AACR, NGS, DNA sequencing, Cancer, Mutation, NSCLC, XNA, MRD, Real-time, Patient, CDX, American Association for Cancer Research, FDA, Medical imaging

PLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023.

Key Points: 
  • PLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023.
  • The presentations will focus on how XNA can be used to improve the assay sensitivity of different technology platforms such as Sanger sequencing, qPCR, and Next Generation Sequencing (NGS).
  • DiaCarta’s XNA technology has demonstrated improvements to the sensitivity of traditional Sanger sequencing to comparable sensitivity levels of NGS, with much broader clinical utility and lower cost.
  • The XNA-based Sanger sequencing and qPCR are used for sensitive companion diagnostics (CDx) assay development for identification of KRAS G12C mutation.

CENTOGENE Launches NEW CentoGenome®, World’s Most Comprehensive Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases

Retrieved on: 
Wednesday, April 12, 2023
SMA, PD, Genomics, Health care, NGS, DNA sequencing, Gaucher's disease, GD, DSM-IV codes, CNV, Whole genome sequencing, Spinal muscular atrophy, Patient, Physician, Combine, WGS, Diagnosis, Polymerase chain reaction, Bias, PCR, Genome, Medical device, Medical imaging

and ROSTOCK, Germany and BERLIN, April 12, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of NEW CentoGenome®, an enhanced Next Generation Sequencing (NGS)-based assay.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, April 12, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of NEW CentoGenome®, an enhanced Next Generation Sequencing (NGS)-based assay.
  • Healthcare professionals can leverage NEW CentoGenome to provide more comprehensive diagnostic information, which could accelerate access to potential treatment options.
  • Serving as a first-line test, NEW CentoGenome is the most comprehensive commercially available Whole Genome Sequencing (WGS) test on the market for both rare and neurodegenerative disorders – covering almost all disease-causing variants, including the most relevant repeat expansions associated with neurological diseases, in a single assay.
  • “Building on this expertise, CENTOGENE’s enhanced whole genome sequencing is the leading solution on the market, reflecting the latest advanced technologies and unique insights that can’t be found anywhere else to provide maximized disease coverage.

OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND

Retrieved on: 
Wednesday, April 5, 2023
Partnership, Antimicrobial stewardship, DNA sequencing, Infection, Research, Global Health Innovative Technology Fund, IP, LMIC, Patient, Medicine, Medical device

The work already completed under the collaboration will be expanded by three work packages increasing total project volume to up to € 830 thousand in revenue potential.

Key Points: 
  • The work already completed under the collaboration will be expanded by three work packages increasing total project volume to up to € 830 thousand in revenue potential.
  • The added deliverables will address the following topics:
    An Antimicrobial Stewardship Module supporting users with rule-based information to allow making the best treatment choices based on respective hospital’s drug availability;
    Next Generation Sequencing (“NGS”) strain analysis including isolates from several sub-Saharan African countries to investigate any potential sequence differences.
  • Dr. Gerd Luedke, Director Innovation, Technology and IP at OpGen’s German subsidiary Curetis GmbH commented: “As we approach the final milestones from the original first phase of our collaboration agreement, we are excited to expand the scope of our R&D partnership with FIND.
  • It will help our team to better evaluate the potential of Unyvero A30 to help identify blood stream infections in patients admitted to LMIC hospitals.”

ALCEDIAG and SYNLAB join forces in Europe to fight diagnostic delay of bipolar disorder with the EDIT-B™ test

Retrieved on: 
Monday, March 27, 2023
CE, Depression, Face, NGS, DNA sequencing, Biomarker, RNA, EPA, Science, Patient, Biology, Artificial intelligence, Diagnosis, AI, Congress, Health, RNA editing, Psychiatry, Bipolar disorder, BD, Nursing, Medical device

EDIT-B™: a reliable, validated and rapid biological response to reduce the diagnostic delay and address an unmet medical need.

Key Points: 
  • EDIT-B™: a reliable, validated and rapid biological response to reduce the diagnostic delay and address an unmet medical need.
  • ALCEDIAG and SYNLAB are making EDIT-B™ , based on RNA editing and AI, available to specialized healthcare professionals and their patients in Europe.
  • The availability of this test will really be a game-changer in the psychiatric area", states Giovanni Gianolli, CEO of SYNLAB Italy.
  • It will be soon available in France and Switzerland during 2023 and gradually in other countries (SYNLAB is present 26 countries in Europe).

Bay Area Lyme Foundation Celebrates Department of Defense CDMRP Tick-borne Disease Awardees

Retrieved on: 
Thursday, March 23, 2023
Columbia University, Tufts University, Duke University, Biobank, Notifiable disease, Doctor of Pharmacy, Virginia Tech, Therapy, Lyme disease, Babesiosis, Frontiers, Gastrointestinal tract, Infection, COVID-19, DNA sequencing, AGS, Immunoglobulin M, PCR, MBA, Research, Immunoglobulin A, Tick, Antibody, Peptidoglycan, Veteran, Tick-Borne Disease Alliance, Johns Hopkins University, Blood transfusion, Patient, Risk, Blood, Immunoglobulin G, DVM, NIH, MBI, Skin, Vaccine, Microbiology, Doctor of Philosophy, MD

PORTOLA VALLEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, announces that two projects it has previously funded have now received Department of Defense Congressionally Directed Medical Research Programs (CDMRP) Tick-Borne Disease awards.

Key Points: 
  • PORTOLA VALLEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, announces that two projects it has previously funded have now received Department of Defense Congressionally Directed Medical Research Programs (CDMRP) Tick-Borne Disease awards.
  • Three of the six recently announced CDMRP awardees will be using biological samples from Bay Area Lyme Foundation’s Lyme Disease Biobank to enable their research into diagnostics and therapeutics for tick-borne diseases, including Lyme disease—which infects half a million people each year.
  • Peter Gwynne, research assistant professor in Hu's lab, was a Bay Area Lyme Foundation ELA winner in 2022 and has used samples from the Lyme Disease Biobank.
  • Jutras was a Bay Area Lyme Foundation ELA winner in 2021 and his lab will be using samples from the Lyme Biobank to validate their novel diagnostics.